000164206 001__ 164206
000164206 005__ 20240227115127.0
000164206 0247_ $$2doi$$a10.3389/fneur.2021.626787
000164206 0247_ $$2pmid$$apmid:33854472
000164206 0247_ $$2pmc$$apmc:PMC8039289
000164206 0247_ $$2altmetric$$aaltmetric:102924761
000164206 037__ $$aDZNE-2022-00862
000164206 041__ $$aEnglish
000164206 082__ $$a610
000164206 1001_ $$aMix, Lucas$$b0
000164206 245__ $$aQuality of Life in SMA Patients Under Treatment With Nusinersen.
000164206 260__ $$aLausanne$$bFrontiers Research Foundation$$c2021
000164206 3367_ $$2DRIVER$$aarticle
000164206 3367_ $$2DataCite$$aOutput Types/Journal article
000164206 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1709023021_12959
000164206 3367_ $$2BibTeX$$aARTICLE
000164206 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164206 3367_ $$00$$2EndNote$$aJournal Article
000164206 520__ $$aBackground: Spinal Muscular Atrophy (SMA) is a severe neurodegenerative disease, characterized by progressive muscle weakness and atrophy. The approval of the antisense oligonucleotide (ASO) nusinersen now provides an effective pharmacological approach with the potential to slow down or stop disease progression with a potentially major impact on patients' well-being. Objective: This study evaluates quality of life (QoL) in pediatric and adult patients over the course of therapy with nusinersen. Methods: Twenty-six SMA patients treated with nusinersen were evaluated regarding global QoL (gQoL), health-related QoL (HRQoL) and depressiveness. Assessments were conducted three times over the first 6 months of treatment. Applied were different questionnaires: the Anamnestic Comparative Self-Assessment (ACSA) for gQoL, the Short Form-36 Health Survey (SF-36) for HRQoL in adult patients and the ALS Depression Inventory 12 Items (ADI-12) for depressiveness. The sample was matched with 22 healthy controls. Results: Despite severe physical restrictions, patients reported high levels of QoL and low levels of depressiveness at study entry. Early disease onset and low levels of physical functioning were associated with better gQoL and lower levels of depressiveness. A significant decrease of gQoL in patients was evident over the course of the study. Still, adult patients reported a significant increase in perceived health. Conclusions: Our study provides first insight that SMA patients experience a gQoL superior to healthy controls at start of therapy. This might indicate patients' high hopes and expectations toward treatment. gQoL returns to a level similar to that of healthy controls over the course of therapy.
000164206 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000164206 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000164206 650_7 $$2Other$$aantisense oligonucleotide
000164206 650_7 $$2Other$$adepressiveness
000164206 650_7 $$2Other$$anusinersen (Spinraza)
000164206 650_7 $$2Other$$apatient reported outcome
000164206 650_7 $$2Other$$aquality of life
000164206 650_7 $$2Other$$aspinal muscular atrophy
000164206 650_7 $$2Other$$awell-being
000164206 7001_ $$aWinter, Benedikt$$b1
000164206 7001_ $$0P:(DE-2719)9002006$$aWurster, Claudia$$b2$$udzne
000164206 7001_ $$aPlaten, Sophia$$b3
000164206 7001_ $$0P:(DE-2719)9001976$$aWitzel, Simon$$b4$$udzne
000164206 7001_ $$aUzelac, Zeljko$$b5
000164206 7001_ $$aGraf, Heiko$$b6
000164206 7001_ $$0P:(DE-2719)2812633$$aLudolph, Albert C$$b7$$udzne
000164206 7001_ $$aLulé, Dorothée$$b8
000164206 773__ $$0PERI:(DE-600)2564214-5$$a10.3389/fneur.2021.626787$$gVol. 12, p. 626787$$p626787$$tFrontiers in neurology$$v12$$x1664-2295$$y2021
000164206 8564_ $$uhttps://pub.dzne.de/record/164206/files/DZNE-2022-00862.pdf$$yOpenAccess
000164206 8564_ $$uhttps://pub.dzne.de/record/164206/files/DZNE-2022-00862.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000164206 909CO $$ooai:pub.dzne.de:164206$$popenaire$$pVDB$$popen_access$$pdnbdelivery$$pdriver
000164206 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002006$$aExternal Institute$$b2$$kExtern
000164206 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001976$$aExternal Institute$$b4$$kExtern
000164206 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812633$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000164206 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000164206 9141_ $$y2021
000164206 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-28
000164206 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000164206 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000164206 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-28
000164206 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000164206 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-28
000164206 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT NEUROL : 2021$$d2022-11-18
000164206 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-18
000164206 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-18
000164206 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T13:11:28Z
000164206 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T13:11:28Z
000164206 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-11T13:11:28Z
000164206 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-18
000164206 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-18
000164206 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-18
000164206 9201_ $$0I:(DE-2719)5000077$$kClinical Study Center Ulm$$lClinical Study Center Ulm$$x0
000164206 980__ $$ajournal
000164206 980__ $$aVDB
000164206 980__ $$aI:(DE-2719)5000077
000164206 980__ $$aUNRESTRICTED
000164206 9801_ $$aFullTexts